CAR-T and engineered T cell therapies

Current State

Chimeric Antigen Receptor (CAR)-T cell therapy has revolutionized cancer treatment, especially for B-cell leukemias and lymphomas, demonstrating remarkable clinical responses and durable remissions (Sterner et al., 2021; June et al., 2018). Approved CAR-T therapies, such as axicabtagene ciloleucel for refractory large B-cell lymphoma and KTE-X19 for relapsed/refractory mantle-cell lymphoma, highlight this success (Neelapu et al., 2017; Wang et al., 2020). Engineered T cell receptor (TCR-T) therapies are also emerging as a promising alternative, particularly for solid tumors, due to their broader target repertoire and high antigen sensitivity (Baulu et al., 2023).

Strongest Evidence

Clinical trials have provided strong evidence for CAR-T efficacy in hematologic malignancies. For instance, bb2121, a BCMA-targeted CAR-T therapy, showed potential in relapsed/refractory multiple myeloma (Raje et al., 2019). The use of CRISPR/Cas9 to engineer universal, dual-targeted CAR-T cells (CD19/CD22) has shown promise in addressing antigen escape in relapsed/refractory B-cell acute lymphoblastic leukemia (Hu et al., 2021). Furthermore, optimizing manufacturing protocols to enrich naive/stem memory T cells enhances antitumor responses while reducing cytokine release syndrome, a major toxicity (Arcangeli et al., 2022).

Unresolved Uncertainties

Despite successes, significant challenges persist. Efficacy in solid tumors remains modest due to barriers like restricted trafficking, the immunosuppressive tumor microenvironment, and antigen escape (Sterner et al., 2021; Baulu et al., 2023; Morotti et al., 2021). Severe life-threatening toxicities, such as cytokine release syndrome and neurotoxicity, are also major concerns (Sterner et al., 2021; June et al., 2018). The complex and costly manufacturing process of autologous CAR-T cells limits accessibility and scalability (Levine et al., 2017).

Why the Topic Matters

CAR-T and engineered T cell therapies represent a paradigm shift in oncology, offering curative potential for patients with otherwise intractable cancers. Continued research into overcoming current limitations, such as improving solid tumor efficacy, mitigating toxicities, and developing more accessible "off-the-shelf" allogeneic products, is crucial. These advancements could broaden the applicability of these therapies, saving more lives and improving patient outcomes across a wider range of cancers.

Points of Agreement

• CAR-T cell therapy has demonstrated remarkable efficacy in treating B-cell leukemias and lymphomas, leading to durable remissions in some patients (Neelapu et al., 2017; Raje et al., 2019; Wang et al., 2020).
• Key toxicities associated with CAR-T cell therapy include cytokine release syndrome (CRS) and neurotoxicity, which require careful management (June et al., 2018; Sterner et al., 2021).
• The manufacturing process for CAR-T cells involves isolating a patient's T cells, genetically engineering them to express a CAR, expanding them, and reinfusing them into the patient (Levine et al., 2017).
• Challenges in CAR-T therapy for solid tumors include limited tumor infiltration, an immunosuppressive tumor microenvironment, and antigen escape (Sterner et al., 2021; Morotti et al., 2021; Baulu et al., 2023).
• Engineered T cell receptor (TCR-T) therapies represent a promising alternative for solid tumors, as they can target intracellular antigens and offer high antigen sensitivity (Baulu et al., 2023; Zhao et al., 2019).

Active Disagreements

• The optimal T-cell subset for CAR-T manufacturing is debated, with some studies suggesting that naive/stem memory T cells enhance antitumor responses while potentially curtailing CRS, compared to unselected T cells (Arcangeli et al., 2022).

Uncertain Claims

• The long-term durability of responses and potential for late-onset toxicities in patients treated with CAR-T cells, particularly in less studied indications, remains an area of ongoing observation.
• The full extent of efficacy for dual-targeted or universal CAR-T cell therapies in preventing antigen escape and improving outcomes in relapsed/refractory B-cell acute lymphoblastic leukemia is still being evaluated in clinical trials (Hu et al., 2021).

Evidence Gaps

• More robust clinical trial data are needed to establish the consistent efficacy and safety of CAR-T and TCR-T cell therapies across a wider range of solid tumors (Morotti et al., 2021; Baulu et al., 2023).
• Further research is required to develop effective strategies for overcoming the immunosuppressive tumor microenvironment in solid tumors to enhance CAR-T cell persistence and function (Sterner et al., 2021).
• There is a need for improved biomarkers to predict response to CAR-T therapy and identify patients at higher risk of severe toxicities (Neelapu et al., 2017).
• Comprehensive studies are needed to optimize manufacturing protocols for CAR-T cells to improve scalability, reduce costs, and enhance product quality for broader global access (Levine et al., 2017).

CAR-T cell therapy has shown strong efficacy in treating hematologic malignancies. For instance, axicabtagene ciloleucel (axi-cel) demonstrated high objective response rates in refractory large B-cell lymphoma (Neelapu et al., 2017). KTE-X19, another anti-CD19 CAR-T therapy, also showed significant benefit in relapsed or refractory mantle-cell lymphoma, particularly in patients who had progressed after BTK inhibitor therapy (Wang et al., 2020). Similarly, bb2121, a BCMA-targeted CAR-T cell therapy, exhibited potential for multiple myeloma treatment, with CAR T-cell expansion correlating with responses and persistence up to a year (Raje et al., 2019).

However, the application of CAR-T cell therapy in solid tumors has been modest due to several limitations, including severe toxicities, limited anti-tumor activity, antigen escape, restricted trafficking, and poor tumor infiltration (Sterner et al., 2021; Morotti et al., 2021). Despite these challenges, there is some weak evidence of efficacy in solid tumors, such as a case report showing regression of glioblastoma after IL13Rα2-targeted CAR T-cell therapy delivered intracranially (Brown et al., 2016).

Engineered T cell receptor (TCR-T) therapies represent a promising alternative for solid tumors. TCR-T cells can target a broader range of antigens, including intracellular proteins, and possess intrinsic features like high antigen sensitivity and physiological signaling, which may improve tumor detection and killing while enhancing T cell persistence (Baulu et al., 2023). Both CAR-T and TCR-T therapies have shown encouraging clinical outcomes in various malignant tumors (Zhao et al., 2019).

Manufacturing processes are critical for CAR-T cell efficacy and safety. Optimizing protocols to enrich naive/stem memory T cells during manufacturing can enhance antitumor responses and reduce cytokine release syndrome (CRS) (Arcangeli et al., 2022). The development of universal, off-the-shelf CAR-T cells, such as CRISPR/Cas9-engineered CD19/CD22 dual-targeted CAR-T cells, aims to overcome delays associated with autologous therapies and address antigen escape (Hu et al., 2021). However, the global manufacturing of CAR-T cells faces challenges in ensuring compliance and scalability as these therapies move into later-phase clinical trials (Levine et al., 2017).

Severe life-threatening toxicities, including CRS and neurologic dysfunction, remain significant limitations of CAR-T cell therapies (Sterner et al., 2021; June et al., 2018). The interaction between host, tumor microenvironment, and CAR-T cells also critically alters CAR-T cell function, impacting therapeutic efficacy (Sterner et al., 2021).

Chimeric Antigen Receptor (CAR)-T cell therapy has revolutionized the treatment of B-cell malignancies, demonstrating remarkable efficacy in conditions like relapsed or refractory mantle-cell lymphoma and multiple myeloma (Wang et al., 2020; Raje et al., 2019; Neelapu et al., 2017). However, its application in solid tumors has been modest, prompting a shift towards alternative engineered T cell approaches and strategies to enhance CAR-T efficacy and safety (Sterner et al., 2021; Baulu et al., 2023; Morotti et al., 2021).

Emerging Methods and Applications:

• TCR-Engineered T Cells (TCR-T): TCR-T cells are emerging as a promising alternative for solid tumors. Unlike CAR-T cells, TCR-T cells can target intracellular antigens, significantly expanding the repertoire of potential targets beyond membrane proteins. This intrinsic feature, coupled with high antigen sensitivity and near-physiological signaling, may improve therapeutic outcomes in solid tumors where CAR-T cells have faced challenges (Baulu et al., 2023; Zhao et al., 2019).
• Dual-Targeted and Universal CAR-T Cells: To combat antigen escape, a significant limitation of single-targeted CAR-T therapies, dual-targeted CAR-T cells are being developed. For instance, CRISPR/Cas9-engineered universal CD19/CD22 dual-targeted CAR-T cells show promise for relapsed/refractory B-cell acute lymphoblastic leukemia, addressing both antigen escape and treatment availability delays associated with autologous therapies (Hu et al., 2021).
• Targeting Glioblastoma: Early clinical signals suggest CAR-T cell therapy can induce regression in glioblastoma, with intracranial infusions of IL13Rα2-targeted CAR T cells showing promise without severe toxic effects (Brown et al., 2016).

Manufacturing and Safety Improvements:

• Optimized Manufacturing Protocols: Advances in manufacturing focus on generating CAR-T cells from naive/stem memory T lymphocytes (TN/SCM). These cells exhibit enhanced expansion and persistence, leading to superior antitumor responses while potentially curtailing severe toxicities like cytokine release syndrome (CRS) (Arcangeli et al., 2022). This approach aims to improve the durability and safety profile of CAR-T cell products.
• Mitigating Toxicities: Severe life-threatening toxicities, including CRS and neurologic dysfunction, remain significant challenges (Sterner et al., 2021; June et al., 2018). Research is ongoing to develop strategies to manage and prevent these adverse events, often through refined cell engineering and patient management protocols (Arcangeli et al., 2022).

Challenges and Future Directions:

Despite progress, challenges persist, including modest anti-tumor activity in solid tumors, restricted trafficking, limited tumor infiltration, and host-related barriers (Sterner et al., 2021). The global manufacturing of CAR-T cell therapy is also a complex process, requiring robust infrastructure as these therapies move into later-phase clinical trials (Levine et al., 2017). Future trends will likely focus on developing "off-the-shelf" allogeneic CAR-T products, further optimizing T cell engineering for enhanced persistence and reduced toxicity, and exploring combination therapies to overcome the immunosuppressive tumor microenvironment in solid tumors.

Synthesis

Engineered T-cell therapies, including Chimeric Antigen Receptor (CAR)-T and T-Cell Receptor (TCR)-T cells, represent a paradigm shift in cancer immunotherapy (June et al., 2018). CAR-T therapy has achieved unprecedented success in treating relapsed or refractory B-cell malignancies like mantle-cell lymphoma, large B-cell lymphoma, and multiple myeloma by targeting antigens such as CD19 and BCMA (Wang et al., 2020; Neelapu et al., 2017; Raje et al., 2019). Despite this, its application is hindered by significant challenges, including severe toxicities, limited efficacy against solid tumors, and the potential for antigen escape (Sterner et al., 2021). TCR-engineered T-cells offer an alternative, with the ability to target a broader range of intracellular antigens, potentially improving efficacy in solid tumors (Baulu et al., 2023).

Methods and Materials

CAR-T cell manufacturing is a complex, personalized process involving the extraction of a patient's T-cells (apheresis), ex vivo genetic engineering to express a CAR, and subsequent expansion before reinfusion (Levine et al., 2017). The CAR construct typically targets a specific tumor surface antigen. Innovations in manufacturing aim to enhance efficacy and safety. For instance, generating CAR-T cells from preselected naive/stem memory T cells (TN/SCM) has been shown to improve antitumor activity and persistence while reducing cytokine release syndrome (Arcangeli et al., 2022). Advanced gene-editing techniques like CRISPR/Cas9 are being used to create 'off-the-shelf' universal CAR-T cells by disrupting genes like TRAC, and to develop dual-targeted therapies (e.g., CD19/CD22) to prevent antigen escape (Hu et al., 2021).

Applications

Clinical applications are most advanced in hematologic cancers. KTE-X19 (axicabtagene ciloleucel) has demonstrated high objective response rates in refractory mantle-cell and large B-cell lymphomas (Wang et al., 2020; Neelapu et al., 2017). Similarly, anti-BCMA CAR-T therapy (bb2121) has shown promise in heavily pretreated multiple myeloma (Raje et al., 2019). Applications are expanding to solid tumors, though with modest success. Promising case studies, such as the regression of glioblastoma using intracranially delivered IL13Rα2-targeted CAR-T cells, highlight the potential but also the unique delivery and microenvironment challenges in these cancers (Brown et al., 2016; Morotti et al., 2021).

Limitations

Key limitations include severe toxicities like cytokine release syndrome (CRS) and neurotoxicity (June et al., 2018). In solid tumors, barriers include restricted T-cell trafficking and infiltration, an immunosuppressive tumor microenvironment, and a lack of unique target antigens (Sterner et al., 2021; Morotti et al., 2021). Antigen escape, where tumors downregulate the target antigen, is a major cause of relapse in hematologic malignancies (Hu et al., 2021). The high cost and complexity of manufacturing also limit accessibility (Levine et al., 2017).

Update Triggers

This review should be updated upon the release of pivotal clinical trial data for new CAR-T or TCR-T constructs, particularly in solid tumors. Significant advancements in manufacturing, such as successful 'off-the-shelf' allogeneic products, or novel strategies to mitigate toxicities or overcome the tumor microenvironment would also warrant an update.

Near-Term Work

• Solid Tumor Targets: Identify and validate novel tumor-associated antigens (TAAs) for solid tumors, moving beyond the successes in hematological malignancies. Focus on targets with high tumor specificity to minimize on-target, off-tumor toxicity.
• Toxicity Mitigation: Develop and refine safety switches (e.g., suicide genes) and strategies to control cytokine release syndrome (CRS) and neurotoxicity. Engineer CAR-T cells with improved logic gates (AND, OR, NOT) to enhance tumor discrimination.
• Allogeneic Platforms: Advance research on "off-the-shelf" allogeneic CAR-T cells from healthy donors to reduce manufacturing time and cost, and overcome patient-specific T-cell quality issues. This includes optimizing gene-editing techniques to prevent graft-versus-host disease (GVHD).

Validation Needs & High-Value Experiments

• Preclinical Models: Develop more predictive in vivo models, including patient-derived xenografts (PDXs) and humanized mouse models, that accurately replicate the tumor microenvironment (TME) of solid tumors.
• High-Value Experiment: Conduct head-to-head comparisons of different CAR constructs (e.g., varying co-stimulatory domains) and engineered TCR-T cells against the same solid tumor models to determine optimal designs for overcoming antigen escape and T-cell exhaustion.

Datasets & Benchmarks

• Datasets: Generate multi-omic longitudinal datasets from clinical trial patients, correlating genomic, transcriptomic, and proteomic data with clinical outcomes (response, resistance, toxicity). Standardize data collection for manufacturing parameters (e.g., T-cell phenotype, transduction efficiency).
• Benchmarks: Establish standardized metrics for clinical efficacy beyond overall response rate, such as durability of response and quality of life. For manufacturing, key benchmarks include vein-to-vein time, cost-per-dose, and scalability.

Translation Barriers

• Manufacturing & Scalability: High costs, complex logistics, and lengthy manufacturing times remain significant barriers. Automation and decentralized manufacturing models are needed.
• TME Resistance: The immunosuppressive TME of solid tumors, characterized by physical barriers, inhibitory ligands (e.g., PD-L1), and suppressive immune cells, is a primary obstacle to efficacy (Sterner et al., 2021; Baulu et al., 2023).
• Antigen Escape: Tumor heterogeneity and loss of the target antigen lead to relapse, a challenge seen even in successful therapies like KTE-X19 for mantle-cell lymphoma (Wang et al., 2020).